Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...
With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
Roche' Tecentriq Subcutaneous Approved In Great Britain For All Indications Of Intravenous Tecentriq
(RTTNews) - Roche (RHHBY) said that its Tecentriq subcutaneous is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung, bladder, breast and liver ...
As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce ...
Merck has talked up the value of its subcutaneous version of Keytruda, arguing that the investigational therapy will increase access to treatment by untethering patients from infusion centers. Roche ...
The CheckMate 67T trials revealed that subcutaneous nivolumab was noninferior to intravenous nivolumab for the treatment of advanced or metastatic clear cell renal cell carcinoma. Subcutaneous ...
A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback